ALFASIGMA

ALFASIGMA is a global pharmaceutical company and contract manufacturer based in Alanno, Italy, with a rich history spanning over 75 years, formed from the merger of Alfa Wassermann and Sigma-Tau. Established in 2015, the company employs between 2,001 and 5,000 people and reported a revenue of –1.87 billion in 2024. ALFASIGMA specializes in a broad range of pharmaceutical products, including Gastroenterology drugs for functional gastro-intestinal disorders, IBD, and chronic liver disease; Vascular disease treatments for venous diseases and diabetic microangiopathies; Rheumatology drugs; and Metabolic disease treatments focusing on Carnitine. Their product portfolio also extends to Nutraceuticals, Medical foods, and Self-medication products. The company operates a factory and provides comprehensive CDMO (Contract Development and Manufacturing Organization) services, including freeze-drying capabilities, offering complete and customized pharmaceutical and nutraceutical solutions. With a significant international presence, ALFASIGMA operates in over 100 markets across Europe, Asia, and the Americas, with direct subsidiaries in numerous countries including China, Germany, India, Mexico, and the USA. They are committed to research and innovation, with ongoing R&D projects in gastroenterology, vascular diseases, and neuroscience, and aim to improve patients' quality of life globally.